CAMBRIDGE, Mass., June 17, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company outpacing cancer to help patients outlive their disease, today ...

CAMBRIDGE, Mass., June 17, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company outpacing cancer to help patients outlive their disease, today ...

Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025 ...

Immuneering Corporation will host a conference call on June 17 to discuss updates on its Phase 2a trial for IMM-1-104.

CAMBRIDGE, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize more effective and better ...

About Immuneering Corporation Immuneering is a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients.

CAMBRIDGE, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize more effective and better ...

Immuneering (NASDAQ:IMRX – Get Free Report) is projected to post its quarterly earnings results before the market opens on Friday, March 7th. Analysts expect Immuneering to post earnings of ($0. ...